Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 9/20 | 0.76 |
| ▸ | AURKA | O14965 | 3/20 | 0.66 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.59 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.59 |
| ▸ | PPARG | P37231 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | CA12 | O43570 | 1/20 | 0.52 |
| ▸ | CA9 | Q16790 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | DRD2 | P14416 | 1/20 | 0.51 |
| ▸ | PTGES | O14684 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4184447 | 0.88 | PTGS2 (0.65) | PTGS2AURKAHDAC1HDAC2PPARG | |
| SCHEMBL28718188 | 0.81 | PTGS2 (0.64) | PTGS2AURKAMAPTKDM4ECA12 | |
| SCHEMBL4186664 | 0.80 | PTGS2 (0.73) | PTGS2AURKAHDAC1HDAC2MAPT | |
| SCHEMBL22095473 | 0.80 | AURKA (1.00) | AURKAHDAC1HDAC2MAPT | |
| SCHEMBL5947916 | 0.80 | AURKA (0.74) | PTGS2AURKAHDAC1HDAC2PPARG | |
| SCHEMBL23928504 | 0.78 | CA12 (0.75) | PTGS2AURKAHDAC1HDAC2PPARG | |
| SCHEMBL11763644 | 0.78 | AURKA (0.53) | PTGS2AURKAHDAC1HDAC2PPARG | |
| SCHEMBL11762309 | 0.77 | AURKA (0.55) | PTGS2AURKAHDAC1HDAC2PPARG | |
| SCHEMBL23928543 | 0.77 | PTGS2 (0.72) | PTGS2AURKAHDAC1HDAC2MAPT | |
| SCHEMBL5698619 | 0.77 | CA9 (0.67) | PTGS2CA12CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8071782-B2 | Synthesis of 1,3,4-trisubstituted and 1,3,4,5-tetrasubstituted pyrazoles | JANSSEN PHARMACEUTICA NV (BE) | 2011-12-06 | — | — | US | disclosed |
| US-8071782-B2 | Synthesis of 1,3,4-trisubstituted and 1,3,4,5-tetrasubstituted pyrazoles | JANSSEN PHARMACEUTICA NV (BE) | 2011-12-06 | — | — | US | disclosed |
| US-8071782-B2 | Synthesis of 1,3,4-trisubstituted and 1,3,4,5-tetrasubstituted pyrazoles | JANSSEN PHARMACEUTICA NV (BE) | 2011-12-06 | — | — | US | disclosed |
| US-20090093637-A1 | Synthesis of 1,3,4-Trisubstituted and 1,3,4,5-Tetrasubstituted Pyrazoles | JANSSEN PHARMACEUTICA NV (BE) | 2009-04-09 | — | — | US | disclosed |
| US-20090093637-A1 | Synthesis of 1,3,4-Trisubstituted and 1,3,4,5-Tetrasubstituted Pyrazoles | JANSSEN PHARMACEUTICA NV (BE) | 2009-04-09 | — | — | US | disclosed |
| US-20090093637-A1 | Synthesis of 1,3,4-Trisubstituted and 1,3,4,5-Tetrasubstituted Pyrazoles | JANSSEN PHARMACEUTICA NV (BE) | 2009-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090093637-A1 | Synthesis of 1,3,4-Trisubstituted and 1,3,4,5-Tetrasubstituted Pyrazoles | CYP3A4, CYP4B1, CYP2E1 | PTGS2 270/4885AURKA 973/4885HDAC1 156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.